Imaging Biometrics (LSE:IBAI) rose 53.3% to 0.92p after announcing positive findings from a prospective multicentre study validating its IB Neuro automated glioblastoma biomarker.
The small-cap medtech firm said, in an announcement on Friday, that a prospective, multicentre cancer study, conducted across 33 centres and 146 patients, and sponsored by ECOG‑ACRIN/NCTN, using fully-automated technology, had outperformed the manual approach.
"The EAF151 results show that the technology built in IB Neuro can provide early, objective signals of treatment response, within weeks rather than months," said Michael Schmainda, Chief Executive Officer of Imaging Biometrics.
Imaging Biometrics said that it plans to monetise IB Neuro by selling to participating EAF151 sites and organisations running anti‑angiogenic trials, including contract research organisations (CROs) and trial sponsors, via direct channels and global distribution partners. It leverages the platform's FDA‑cleared, UKCA‑ and CE‑marked status and existing distributors to generate incremental revenue without material external funding.
What the study showed
The imaging technology, part of the processing in CT and MRI, was used in a trial in which a fully automated type of metric (sRCBV), via IB Neuro, outperformed manually normalized Relative Cerebral Blood Volume (rCBV) (the neuroimaging metric used in CT and MRI) in predicting overall survival in a form of cancer, recurrent glioblastoma.
In Friday's statement, the company said centralised image processing by the ACRIN core lab generated IB Delta T1 maps to define contrast‑enhancing regions, and both baseline and two‑week post‑treatment rCBV measures showed meaningful associations with patient outcomes.
As a result, the company claimed it positions sRCBV as one of the first prospectively validated automated advanced imaging biomarkers for overall survival (OS) prediction in recurrent glioblastoma.
